New mRNA vaccine aims to shield seniors from RSV
NCT ID NCT07128121
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study tests a new mRNA vaccine called IN006 to see if it is safe and helps the immune system fight respiratory syncytial virus (RSV) in healthy adults aged 60 and older. About 500 participants will receive either the vaccine or a placebo, and researchers will monitor side effects and antibody levels over time. Some participants may get a booster shot after 12 or 24 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Provincial Center for Disease Control and Prevention
Changsha, Hunan, China
Conditions
Explore the condition pages connected to this study.